| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0005 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0005 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.18 | 0.001 |
| mRNA | WZ8040 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.001 |
| mRNA | LY317615 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.002 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.002 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | -0.12 | 0.002 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.002 |